- Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA® ▼(burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)
- MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid Congress
- MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022
- MEI Pharma and Kyowa Kirin Announce Acceptance of Abstract for Presentation at the American Society of Clinical Oncology Annual Meeting 2022
- LUCA Science and Kyowa Kirin Announce Joint Research Agreement on Mitochondrial Disease Treatment With Novel Mitochondria Modality
- MEI Pharma and Kyowa Kirin Announce Acceptance of Two Abstracts for Presentation at the European Hematology Association 2022 Hybrid Congress
More ▼
Key statistics
On Friday, Kyowa Kirin Co Ltd (4151:TYO) closed at 3,090.00, 18.66% above the 52 week low of 2,604.00 set on May 10, 2022.
52-week range
Markit short selling activity
Open | 3,075.00 |
---|---|
High | 3,095.00 |
Low | 3,050.00 |
Bid | 3,085.00 |
Offer | 3,095.00 |
Previous close | 3,025.00 |
Average volume | 1.12m |
---|---|
Shares outstanding | 540.00m |
Free float | 249.90m |
P/E (TTM) | 29.95 |
Market cap | 1.67tn JPY |
EPS (TTM) | 103.19 JPY |
Annual div (ADY) | 46.00 JPY |
---|---|
Annual div yield (ADY) | 1.49% |
Div ex-date | Dec 29 2021 |
Div pay-date | Mar 28 2022 |
Next div ex-date | Jun 29 2022 |
Next div pay-date | -- |
Data delayed at least 20 minutes, as of Jun 24 2022 07:00 BST.
More ▼